According to an announcement made by GI Dynamics Inc., new data results demonstrate that the EndoBarrier®, a new device for the treatment of type 2 diabetes and/or obesity, is feasible and can be re-implanted safely. EndoBarrier is a pioneering device for the treatment of type 2 diabetes and/or obesity. 13 clinical trials in over 500 patients demonstrated several of the device's benefits, including decreasing HbA1c levels, achieving a loss of weight of more than 20%, as well as improving significant important metabolic measures, such as cholesterol, blood sugar and triglycerides...
More...
More...